RANI

Rani Therapeutics Holdings, Inc.

Price Chart

Latest Quote

$0.78

+0.02 (+2.25%)

Current Price

Previous Close	$0.77
Open	$0.77
Day High	$0.79
Day Low	$0.77
Volume	308,786

Fetched: 2026-06-21T17:24:34

Stock Information

Shares Outstanding	112.39M
Total Debt	$3.94M
Cash Equivalents	$43.40M
Revenue	$3.17M
Net Income	$-29.44M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$107.57M
EPS (TTM)	$-0.27
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$45.85M
Sales	$3.17M
Income	$-29.44M
Book/sh	$0.28
Cash/sh	$0.39
Employees	69

Financial Ratios

Quick Ratio	3.28
Current Ratio	3.40
Debt/Eq	11.09

Returns & Margins

ROA	-56.96%
ROE	-239.96%
Gross Margin	100.00%
Operating Margin	-488.23%

Ownership

Insider Ownership	5.01%
Institutional Ownership	43.87%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-3.56
P/S	33.94
P/B	2.75

Analyst Data

Recommendation	none
Target Price	$7.50

Technical Indicators

SMA20	$0.87
SMA50	$0.91
SMA200	$1.17
RSI	27.10
ATR	0.0543

Shares Float	70.78M
Short Float	6.75%
Short Ratio	7.00
Rel Volume	0.33

Performance History

Week	-2.49%
Month	-11.54%
Quarter	-32.00%
6 Months	-45.69%
YTD	-42.50%
Year	+52.14%
3 Years	-83.91%
10 Years	-92.89%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$0.78	308,800
2026-06-17	$0.76	556,300
2026-06-16	$0.76	750,600
2026-06-15	$0.77	793,000
2026-06-12	$0.76	907,100
2026-06-11	$0.80	564,200
2026-06-10	$0.78	572,500
2026-06-09	$0.81	1,232,300
2026-06-08	$0.84	488,400
2026-06-05	$0.83	846,100
2026-06-04	$0.90	710,300
2026-06-03	$0.88	718,600
2026-06-02	$0.86	1,466,700
2026-06-01	$0.90	2,041,500
2026-05-29	$0.95	1,004,700
2026-05-28	$0.95	1,093,100
2026-05-27	$0.95	804,700
2026-05-26	$0.94	1,942,900
2026-05-22	$1.07	764,300
2026-05-21	$1.07	1,034,900
2026-05-20	$1.09	2,457,900
2026-05-19	$0.88	1,285,100

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The have a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; and Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

📰 Latest News

This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year

Simply Wall St. • 2026-05-08T11:11:01Z

Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth

Simply Wall St. • 2026-03-28T12:00:33Z

Rani Therapeutics Q4 Earnings Call Highlights

MarketBeat • 2026-03-26T21:48:59Z

Largest borrow rate increases among liquid names

TipRanks • 2026-01-24T13:45:19Z

Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%

Simply Wall St. • 2026-01-23T10:20:43Z

H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential

Insider Monkey • 2025-10-26T10:05:52Z

Trending tickers: Apple, Beyond Meat, Rani Therapeutics, BitMine and B&M

Yahoo Finance UK • 2025-10-20T10:53:34Z

Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost

Simply Wall St. • 2025-10-20T03:10:14Z

Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What’s Changed

Simply Wall St. • 2025-10-18T18:07:19Z

Top Midday Gainers

MT Newswires • 2025-10-17T17:58:50Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$1,633,000	$1,028,000	$0	$0
Operating Revenue	$1,633,000	$1,028,000	$0	$0
Expenses
Interest Expense	$2,891,000	$5,033,000	$5,085,000	$1,071,000
Total Expenses	$39,943,000	$50,628,000	$66,099,000	$63,451,000
Other Income Expense	$-576,000	$-3,714,000	-	-
Net Non Operating Interest Income Expense	$-2,064,000	$-3,270,000	$-1,784,000	$177,000
Interest Expense Non Operating	$2,891,000	$5,033,000	$5,085,000	$1,071,000
Operating Expense	$39,943,000	$50,628,000	$66,099,000	$63,451,000
General And Administrative Expense	$19,738,000	$23,946,000	$26,475,000	$26,844,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-29,673,000	$-30,018,000	$-33,970,000	$-30,588,000
Net Interest Income	$-2,064,000	$-3,270,000	$-1,784,000	$177,000
Interest Income	$827,000	$1,763,000	$3,301,000	$1,248,000
Normalized Income	$-29,097,000	$-26,304,000	$-33,970,000	$-30,588,000
Net Income From Continuing And Discontinued Operation	$-29,673,000	$-30,018,000	$-33,970,000	$-30,588,000
Total Operating Income As Reported	$-38,310,000	$-53,314,000	$-66,099,000	$-63,451,000
Net Income Common Stockholders	$-29,673,000	$-30,018,000	$-33,970,000	$-30,588,000
Net Income	$-29,673,000	$-30,018,000	$-33,970,000	$-30,588,000
Net Income Including Noncontrolling Interests	$-40,950,000	$-56,584,000	$-67,883,000	$-63,344,000
Net Income Continuous Operations	$-40,950,000	$-56,584,000	$-67,883,000	$-63,344,000
Pretax Income	$-40,950,000	$-56,584,000	$-67,883,000	$-63,274,000
Special Income Charges	$-576,000	$-3,714,000	$0	$0
Interest Income Non Operating	$827,000	$1,763,000	$3,301,000	$1,248,000
Operating Income	$-38,310,000	$-49,600,000	$-66,099,000	$-63,451,000
Per Share
Diluted EPS	$-0.45	$-1.05	$-1.33	$-1.28
Basic EPS	$-0.45	$-1.05	$-1.33	$-1.28
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-36,583,000	$-46,809,000	$-61,976,000	$-61,655,000
Total Unusual Items	$-576,000	$-3,714,000	$0	$0
Total Unusual Items Excluding Goodwill	$-576,000	$-3,714,000	$0	$0
Reconciled Depreciation	$900,000	$1,028,000	$822,000	$548,000
EBITDA (Bullshit earnings)	$-37,159,000	$-50,523,000	$-61,976,000	$-61,655,000
EBIT	$-38,059,000	$-51,551,000	$-62,798,000	$-62,203,000
Diluted Average Shares	$66,138,000	$28,476,000	$25,505,000	$23,817,000
Basic Average Shares	$66,138,000	$28,476,000	$25,505,000	$23,817,000
Diluted NI Availto Com Stockholders	$-29,673,000	$-30,018,000	$-33,970,000	$-30,588,000
Minority Interests	$11,277,000	$26,566,000	$33,913,000	$32,756,000
Other Special Charges	$576,000	-	-	-
Write Off	$0	$3,714,000	$0	-
Research And Development	$20,205,000	$26,682,000	$39,624,000	$36,607,000
Selling General And Administration	$19,738,000	$23,946,000	$26,475,000	$26,844,000
Other Gand A	$19,738,000	$23,946,000	$26,475,000	$26,844,000
Impairment Of Capital Assets	-	$3,714,000	$0	-
Tax Provision	-	-	$0	$70,000
Gain On Sale Of Security	-	-	-	-

Fetched: 2026-06-14

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$33,010,000	$1,992,000	$12,866,000	$36,855,000
Total Assets	$58,621,000	$36,634,000	$57,916,000	$108,027,000
Total Non Current Assets	$5,300,000	$6,890,000	$7,069,000	$7,103,000
Other Non Current Assets	$246,000	$246,000	$246,000	-
Current Assets	$53,321,000	$29,744,000	$50,847,000	$100,924,000
Other Current Assets	$1,570,000	$1,677,000	$2,308,000	$2,442,000
Receivables	$2,042,000	$428,000	$0	-
Accounts Receivable	$2,042,000	$0	-	-
Cash Cash Equivalents And Short Term Investments	$49,709,000	$27,639,000	$48,539,000	$98,482,000
Cash And Cash Equivalents	$18,618,000	$3,762,000	$5,864,000	$27,007,000
Other Receivables	-	$428,000	-	-
Restricted Cash	-	-	-	$500,000
Prepaid Assets	-	-	-	-
Notes Receivable	-	-	-	-
Debt
Total Debt	$4,318,000	$29,709,000	$30,099,000	$30,214,000
Long Term Debt And Capital Lease Obligation	$2,732,000	$13,250,000	$24,484,000	$29,208,000
Current Debt And Capital Lease Obligation	$1,586,000	$16,459,000	$5,615,000	$1,006,000
Net Debt	-	$20,851,000	$23,517,000	$2,142,000
Long Term Debt	-	$9,613,000	$24,484,000	$29,149,000
Current Debt	-	$15,000,000	$4,897,000	-
Other Current Borrowings	-	$15,000,000	$4,897,000	-
Liabilities
Total Liabilities Net Minority Interest	$17,109,000	$33,141,000	$32,473,000	$34,023,000
Total Non Current Liabilities Net Minority Interest	$4,440,000	$13,250,000	$24,484,000	$29,208,000
Non Current Deferred Liabilities	$1,708,000	$0	-	-
Current Liabilities	$12,669,000	$19,891,000	$7,989,000	$4,815,000
Other Current Liabilities	$46,000	$283,000	$254,000	$538,000
Current Deferred Liabilities	$6,831,000	$0	-	-
Payables And Accrued Expenses	$4,206,000	$3,149,000	$2,120,000	$3,271,000
Interest Payable	$0	$931,000	$500,000	$69,000
Payables	$309,000	$1,359,000	$648,000	$1,513,000
Accounts Payable	$309,000	$1,359,000	$648,000	$1,460,000
Derivative Product Liabilities	-	-	-	-
Equity
Common Stock Equity	$33,010,000	$1,992,000	$12,866,000	$36,855,000
Total Equity Gross Minority Interest	$41,512,000	$3,493,000	$25,443,000	$74,004,000
Stockholders Equity	$33,010,000	$1,992,000	$12,866,000	$36,855,000
Gains Losses Not Affecting Retained Earnings	$1,000	$5,000	$-12,000	$-73,000
Retained Earnings	$-132,580,000	$-102,907,000	$-72,889,000	$-38,919,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$97,622,000	$33,430,000	$26,036,000	$25,295,000
Share Issued	$97,622,000	$33,430,000	$26,036,000	$25,295,000
Tangible Book Value	$33,010,000	$1,992,000	$12,866,000	$36,855,000
Invested Capital	$33,010,000	$26,605,000	$42,247,000	$66,004,000
Working Capital	$40,652,000	$9,853,000	$42,858,000	$96,109,000
Capital Lease Obligations	$4,318,000	$5,096,000	$718,000	$1,065,000
Total Capitalization	$33,010,000	$11,605,000	$37,350,000	$66,004,000
Minority Interest	$8,502,000	$1,501,000	$12,577,000	$37,149,000
Additional Paid In Capital	$165,578,000	$104,889,000	$85,762,000	$75,842,000
Capital Stock	$11,000	$5,000	$5,000	$5,000
Common Stock	$11,000	$5,000	$5,000	$5,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$1,708,000	$0	-	-
Long Term Capital Lease Obligation	$2,732,000	$3,637,000	$0	$59,000
Current Deferred Revenue	$6,831,000	$0	-	-
Current Capital Lease Obligation	$1,586,000	$1,459,000	$718,000	$1,006,000
Current Accrued Expenses	$3,897,000	$1,790,000	$1,472,000	$1,758,000
Net PPE	$5,054,000	$6,644,000	$6,823,000	$7,103,000
Accumulated Depreciation	$-5,540,000	$-4,640,000	$-3,671,000	$-2,849,000
Gross PPE	$10,594,000	$11,284,000	$10,494,000	$9,952,000
Leases	$1,655,000	$1,655,000	$1,588,000	$1,549,000
Construction In Progress	$31,000	$31,000	$3,904,000	$4,416,000
Other Properties	$8,577,000	$9,329,000	$4,741,000	$3,726,000
Machinery Furniture Equipment	$331,000	$269,000	$261,000	$261,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$31,091,000	$23,877,000	$42,675,000	$71,475,000
Dueto Related Parties Current	-	-	$52,000	$53,000

Fetched: 2026-06-14

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-18,802,000	$-35,764,000	$-52,465,000	$-48,134,000
Operating Activities
Operating Cash Flow	$-18,714,000	$-35,496,000	$-51,236,000	$-46,515,000
Cash Flow From Continuing Operating Activities	$-18,714,000	$-35,496,000	$-51,236,000	$-46,515,000
Operating Gains Losses	$743,000	$65,000	-	-
Investing Activities
Capital Expenditure	$-88,000	$-268,000	$-1,229,000	$-1,619,000
Investing Cash Flow	$-7,030,000	$19,809,000	$29,860,000	$-72,436,000
Cash Flow From Continuing Investing Activities	$-7,030,000	$19,809,000	$29,860,000	$-72,436,000
Financing Activities
Issuance Of Capital Stock	$52,599,000	$18,262,000	$0	$0
Financing Cash Flow	$40,300,000	$13,585,000	$233,000	$29,005,000
Cash Flow From Continuing Financing Activities	$40,300,000	$13,585,000	$233,000	$29,005,000
Net Other Financing Charges	$-59,000	$-47,000	$-162,000	$-886,000
Net Common Stock Issuance	$52,599,000	$18,262,000	$0	$0
Common Stock Issuance	$52,599,000	$18,262,000	$0	$0
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
Repayment Of Debt	$-20,722,000	$-5,000,000	$0	$0
Interest Paid Supplemental Data	$2,121,000	$4,112,000	$4,182,000	$730,000
Income Tax Paid Supplemental Data	$0	$0	$35,000	$48,000
End Cash Position	$18,818,000	$4,262,000	$6,364,000	$27,507,000
Beginning Cash Position	$4,262,000	$6,364,000	$27,507,000	$117,453,000
Changes In Cash	$14,556,000	$-2,102,000	$-21,143,000	$-89,946,000
Proceeds From Stock Option Exercised	$8,482,000	$370,000	$395,000	$317,000
Net Issuance Payments Of Debt	$-20,722,000	$-5,000,000	$0	$29,574,000
Net Long Term Debt Issuance	$-20,722,000	$-5,000,000	$0	$29,574,000
Long Term Debt Payments	$-20,722,000	$-5,000,000	$0	$0
Net Investment Purchase And Sale	$-6,942,000	$20,077,000	$31,089,000	$-70,817,000
Sale Of Investment	$26,750,000	$77,550,000	$104,350,000	$3,000,000
Purchase Of Investment	$-33,692,000	$-57,473,000	$-73,261,000	$-73,817,000
Net PPE Purchase And Sale	$-88,000	$-268,000	$-1,229,000	$-1,619,000
Purchase Of PPE	$-88,000	$-268,000	$-1,229,000	$-1,619,000
Change In Working Capital	$6,958,000	$-544,000	$-2,140,000	$509,000
Change In Other Working Capital	$8,539,000	-	-	-
Change In Other Current Liabilities	$-1,909,000	$-1,808,000	$-1,042,000	$-764,000
Change In Payables And Accrued Expense	$2,134,000	$1,061,000	$-1,135,000	$768,000
Change In Accrued Expense	$3,184,000	$350,000	$-540,000	$605,000
Change In Payable	$-1,050,000	$711,000	$-595,000	$163,000
Change In Account Payable	$-1,050,000	$711,000	$-595,000	$163,000
Change In Prepaid Assets	$-192,000	$631,000	$282,000	$505,000
Change In Receivables	$-1,614,000	$-428,000	$0	-
Changes In Account Receivables	$-2,042,000	$0	-	-
Other Non Cash Items	$2,115,000	$2,041,000	$1,273,000	$841,000
Stock Based Compensation	$11,798,000	$16,031,000	$19,008,000	$15,782,000
Asset Impairment Charge	$0	$3,714,000	$0	-
Amortization Of Securities	$-278,000	$-1,247,000	$-2,316,000	$-851,000
Depreciation Amortization Depletion	$900,000	$1,028,000	$822,000	$548,000
Depreciation And Amortization	$900,000	$1,028,000	$822,000	$548,000
Gain Loss On Investment Securities	$167,000	-	-	-
Gain Loss On Sale Of PPE	$0	$65,000	$0	-
Net Income From Continuing Operations	$-40,950,000	$-56,584,000	$-67,883,000	$-63,344,000
Change In Other Current Assets	-	$0	$-245,000	$0
Issuance Of Debt	-	-	$0	$29,574,000
Long Term Debt Issuance	-	-	$0	$29,574,000
Depreciation	-	-	$800,000	$500,000

Fetched: 2026-06-14